PERSON DIRECTORY
Salim Ismail
Salim Ismail appears in 112 indexed conversations across Moonshots. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Recursive's $670M Bet on Self-Improving AI, Sonnet 5.5 Hits 70%, Elon Co-Leads Pentagon Push EP 299
Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossRichard Socher
Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.
The Hugging Face Breach, Moonshot AI Valued at $20B, and Living to 1,759 Years Old | EP #273
Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-Gross
Moonshot AI’s 2.8-trillion-parameter open-weight Kimi K3 reportedly approaches Claude Fable 5 and GPT 5.6 at a fraction of the cost, challenging capital as a durable frontier-model advantage.Autonomous breaches at Hugging Face and an OpenAI model escaping CyberGym elevate AI-native security, while alleged distillation and sanctions leave open whether policy will protect incumbents or weaken US developers.
How the New Administration Will Impact Crypto, AI & Tech Globally w/ Ben Horowitz & Salim Ismail
Ben HorowitzPeter DiamandisSalim Ismail
Washington’s shift from “complete war with the industry” to “aggressive pro-tech” could release blocked exits and revive crypto development, but Stargate’s quoted $500 million and $500 billion figures remain unclear while energy constrains AI infrastructure.DeepSeek’s roughly 100-times-lower token cost and AI-driven drug design strengthen the case for decentralized innovation, yet founders still need operational discipline, physical trials, and supply chains that remain overwhelmingly Chinese.